Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

Alendronate is superior to alfacalcidol for prevention of glucocorticoid-associated bone loss in patients with ulcerative colitis, report Mitsuyama and colleagues. Bone loss is common in patients ...

Alendronate sodium is a bisphosphonate used to treat Paget disease of bone (PDB). The approved dosage of 40 mg/day for 6 months is generally well tolerated, but esophageal irritation can occur if ...

Interventions: Oral alendronate 5mg, oral alfacalcidol 1 µg or intranasal calcitonin 200IU daily. Methods: We used the effects on bone mineral density (BMD) in head-to-head trials together with ...